Aduquaye, M.; Dube, S.; Bashir, B.; Chowdhury, A.; Ahmed, N.; Leylek, A.; Kim, J.; Lambert, P.; Bucher, O.; Hunter, W.;
et al. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Curr. Oncol. 2022, 29, 193-208.
https://doi.org/10.3390/curroncol29010019
AMA Style
Aduquaye M, Dube S, Bashir B, Chowdhury A, Ahmed N, Leylek A, Kim J, Lambert P, Bucher O, Hunter W,
et al. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Current Oncology. 2022; 29(1):193-208.
https://doi.org/10.3390/curroncol29010019
Chicago/Turabian Style
Aduquaye, Marina, Sheen Dube, Bashir Bashir, Amitava Chowdhury, Naseer Ahmed, Ahmet Leylek, Julian Kim, Pascal Lambert, Oliver Bucher, William Hunter,
and et al. 2022. "Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy" Current Oncology 29, no. 1: 193-208.
https://doi.org/10.3390/curroncol29010019
APA Style
Aduquaye, M., Dube, S., Bashir, B., Chowdhury, A., Ahmed, N., Leylek, A., Kim, J., Lambert, P., Bucher, O., Hunter, W., Sivananthan, G., Koul, R., & Rathod, S.
(2022). Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. Current Oncology, 29(1), 193-208.
https://doi.org/10.3390/curroncol29010019
